Quanterix Grants 336,804 RSUs to Three New Employees Under Nasdaq Inducement Rule
核心洞察
Quanterix Corporation (搜索) announced inducement grants totaling 336,804 restricted stock units to three newly hired employees on June 15, 2026.
The RSUs vest in four equal annual installments contingent on continued employment, granted under the Amended and Restated 2025 Inducement Plan.
The grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment.
Quanterix Corporation (搜索) (NASDAQ: QTRX), a company focused on accelerating biomarker breakthroughs from discovery to diagnostics, announced on June 16, 2026 that inducement grants were made to three employees on June 15, 2026, in connection with the commencement of their employment. The inducement grants consisted of 336,804 restricted stock units (RSUs), representing an equivalent number of shares of Quanterix common stock.
The RSUs are structured to vest in four equal installments on the first four anniversaries of the grant date, subject to each individual's continued employment with the Company or one of its subsidiaries through the applicable vesting date.
The inducement grants were issued under the Company's Amended and Restated 2025 Inducement Plan and were approved by the Compensation Committee of Quanterix's Board of Directors. The grants serve as a material inducement for the three individuals entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Quanterix's Expanding Platform
Quanterix has established itself as a global leader in ultra-sensitive biomarker detection, with its proprietary Simoa technology delivering industry-leading sensitivity that enables researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. The company's technology has been validated through approximately 6,500 peer-reviewed publications over nearly two decades.
In 2025, Quanterix expanded its capabilities through the acquisition of Akoya Biosciences, The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio along with 1,450 installed instruments. The combined entity now offers an integrated platform connecting biology across blood and tissue, advancing precision medicine from discovery to diagnostics.